The best regulatory intelligence software for medical device teams in 2026
Device regulatory work runs on precedent more than almost any other corner of life sciences: the whole 510(k) pathway is an argument about what already cleared. This ranks the tools by whether they can actually find that precedent and show you the page. Jurisdiction counts come second.
Why device precedent is its own problem
The device pathway is built on comparison. A 510(k) is a written argument that your product is substantially equivalent to something FDA already let through, so the question isn't "what does the regulation say," it's "which predicate, and what did FDA accept from the people who cited it before us?" Get that wrong and you've either picked a predicate that invites an NSE letter or you've over-tested by six months and a budget cycle.
That makes device regulatory intelligence a search problem with an awkward shape. The answers live in clearance letters, decision summaries, and De Novo classification orders: thousands of individual documents, many of them scanned, none of them written to be compared with each other. Product codes drift. The same technology gets described three different ways across five years of clearances. And a keyword search can't tell you the thing you actually need: across the last thirty products like ours, what testing showed up every single time, and what did nobody bother with?
Two more device-specific wrinkles most tools ignore. Standards, because the ISO/IEC consensus standards FDA recognizes are their own literature, and the gap between what a standard says and how it applies to your form factor is where device teams lose weeks. And quality, which in devices isn't a separate department's problem: 483 themes and warning letters in your product area are regulatory intelligence, because they tell you what the agency is worried about before you ever file.
Methodology & scoring
Facts from public materials as of August 2026, plus what device RA teams tell us about the market in our own conversations.
- Device precedent depth — clearances, De Novos, PMAs, decision summaries, classification orders
- Traceability — does a claim open to the underlying page or passage?
- Standards and quality reach — recognized consensus standards, 483s, warning letters, recalls
- AI / askability — can a reviewer-facing question be asked in plain language?
- Price transparency
Ranked for device regulatory teams
Rhizome AI
Best for predicate and precedent research you can citeRhizome is a focused, AI regulatory coworker, and device precedent is the job it was shaped around: what has your regulator cleared, on what evidence, and what does that mean for your submission. Ask "what predicates have recent AI/ML radiology devices cited, and what testing did FDA require?" and the agents read the actual clearance record (hundreds of documents on a question like that, sometimes thousands) and hand back a synthesized answer where every claim opens to the exact passage of the exact 510(k).
The corpus reaches the parts of device work that fall between departments: clearances, De Novo orders, and PMA records sit alongside recognized consensus standards, 483s, warning letters, and recalls: >45 million documents across >75 health-authority databases in >12 markets as of August 2026, on pace for >150 databases and >25 markets by year end. Every scanned page is processed, which matters more in devices than anywhere else, since so much of the older clearance record is image-only PDF.
Nothing is substantiated from model memory; we benchmark our agents on that discipline specifically. No hallucinations reported in 18 months — a track record, not a guarantee, which is why every citation opens to the page. Free tier, published pricing, and it connects into Claude, ChatGPT, or Copilot over MCP.
Cortellis (Clarivate)
Best curated breadth, if devices are part of a wider portfolioCortellis is the incumbent most often already in the building, and for global regulatory-change tracking across many markets its curated coverage is real, with alerts that buyers consistently credit.
For device precedent specifically it's a weaker fit, and the reason is structural: the product is built on curated summaries of regulations and guidances, and the device pathway's raw material (individual clearance letters and decision summaries) isn't summary-shaped. Device teams end up back in the primary documents anyway. Enterprise custom quote, with startup plus annual fees buyers describe as substantial.
IQVIA Regulatory Intelligence
Widest market reach: a requirements library for global device registrationCredit where it's due: IQVIA RI covers regulatory requirements for devices and IVDs (alongside drugs and biologics) across 110+ countries, regions, and international organizations, with cross-country comparison and change alerting. That's broader geographic reach than we have, and if you're registering a device in market number sixty it's exactly the right tool.
What a requirements library can't hold is the decision layer: the clearance record, decision summaries, and testing precedent showing what an authority actually accepted. For device work that layer is most of the value, because the pathway argues from precedent and the rule text alone doesn't carry it. The catalog gives your RA team the requirement and leaves the "so what do we do" call unsupported, which is the part they'd most like evidence for. It's a search-and-filter surface too, so the synthesis stays with you.
General AI alone (ChatGPT, Claude, Gemini, Copilot)
Fine for concepts, dangerous for predicate claimsAlready paid for and instantly askable, and for explaining a pathway concept or drafting text you already trust, genuinely useful. The catch is structural: the clearance record is largely scanned PDF in databases the open web doesn't index well, so a general assistant answers from memory and press coverage: the famous devices, while the thirty products like yours stay invisible. Ask it for predicates and you'll get plausible-looking K-numbers that need checking one by one, which is the failure mode buyers describe: the citation stops surviving the click. Copilot has the tenant version of the problem, in that it keeps returning your own design files when you asked about the outside world.
Keep the assistant. Connect Rhizome over MCP for anything that ends up in a submission.
In-house AI (internal bots on FDA device files)
The build path, right when the AI is your productDevice engineering teams are especially prone to this one, and the demo works: scrape some clearances, embed them, ask a question. Then the structural costs land: OCR for the scanned back-catalog, weekly refresh across authorities, product-code drift, and an evaluation harness nobody scoped. A snapshot corpus answers confidently without the clearance from last quarter, and in a predicate argument that gap is the whole risk.
The strategic version: build AI where it differentiates you. Your algorithm, your CAD, your test data — that's IP worth engineering around. Reading the public clearance record isn't; nobody differentiates on it.
FDA databases by hand
Free, traceable, and slowThe 510(k) database, the De Novo listing, the recognized-standards database, a spreadsheet, and discipline. Everything is public and every citation is by definition real. The cost is that comparison across thirty products is a week of someone's life, so it gets scoped down to five, and the pattern you needed lived in the twenty-five you skipped.
Choosing by the job in front of you
Leveraged by large pharma, independent consultants, and everyone in between
“Last time we did this research, we spent weeks. Rhizome found the answer immediately.”
“Chetan idk what kind of magic you all did here, it's so good!”
“I want this. I'm really impressed by the quality of the information and the level of detail.”